Millennium Management
ATXI

Millennium Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Millennium Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-140
Closed -$1.55K – 6675
2024
Q1 		$1.55K Sell
140
-241
-63% -$2.85K ﹤0.01% 6084
2023
Q4 		$4.65K Buy
+381
New +$8.91K ﹤0.01% 5829
2022
Q3 		– Sell
-10
Closed -$3K – 7591
2022
Q2 		$3K Hold
10
– – ﹤0.01% 6834
2022
Q1 		$6K Sell
10
-52
-84% -$38.9K ﹤0.01% 6770
2021
Q4 		$63K Buy
62
+3
+5% +$4.34K ﹤0.01% 6416
2021
Q3 		$98K Sell
59
-6
-9% -$12.4K ﹤0.01% 6446
2021
Q2 		$183K Buy
+65
New +$321K ﹤0.01% 6054
2020
Q2 		– Sell
-63
Closed -$631K – 4687
2020
Q1 		$631K Buy
+63
New +$631K ﹤0.01% 2744
2017
Q4 		– Sell
-42
Closed -$258K – 4138
2017
Q3 		$258K Buy
+42
New +$308K ﹤0.01% 3123

Other funds holding ATXI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management's ATXI Position: Q2 2024 in Review

Millennium Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2024, closing a stake of 140 shares — an estimated $1.55K sold.

Millennium Management first reported a position in ATXI in Q3 2017 and held it in 9 quarters. The position peaked at $631K in Q1 2020. 9 funds tracked by Wall St. Rank hold ATXI as of Q2 2024.

  • Millennium Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Millennium Management sold 140 Avenue Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.55K.
  • Millennium Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
  • Millennium Management's Avenue Therapeutics, Inc. Common Stock position peaked at $631K in Q1 2020.
  • 9 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.